Results 231 to 240 of about 99,964 (316)

Systemic and ocular complications related to intravitreal administration of anti-VEGF agents. [PDF]

Med Hypothesis Discov Innov Ophthalmol
Koksaldi S, Kayabasi M, Karti O, Saatci AO.   +3 more
europepmc   +1 more source

Exudative retinopathy from retinal vasoproliferative tumor refractory to aflibercept treated with faricimab-svoa. [PDF]

Am J Ophthalmol Case Rep
Karthik N, Abid SF, Zheng Y, Materin M, Chen X.   +4 more
europepmc   +1 more source

Expanding horizons of intravitreal anti-vascular endothelial growth factor therapy in retinal diseases. [PDF]

Indian J Ophthalmol
Singh S, Kala U, Bamel A, Agarwal M.
europepmc   +1 more source

Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report. [PDF]

Am J Case Rep
Sano H, Yanai R, Mitamura Y.
europepmc   +1 more source

Comparison of the clinical effect of intravitreal ranibizumab and intravitreal dexamethasone implants in the treatment of retinal vein occlusion complicated with macular oedema: a meta-analysis. [PDF]

BMC Ophthalmol
Li Y, Hu L, Zu J.
europepmc   +1 more source

Response to comments on "Intravitreal triamcinolone acetonide therapy in serpiginous-like choroiditis". [PDF]

Indian J Ophthalmol
Kawali A, Mishra SB, Mahendradas P.
europepmc   +1 more source

Faricimab for choroidal neovascular membrane secondary to choroidal osteoma: A case report. [PDF]

J Int Med Res
Al Adel F, Alnfaiei JS, Alzahrani AA, Alotaibi WN.   +3 more
europepmc   +1 more source

Dose-Response Characteristics of Retinal Inactivation Due to Intravitreal Injections of Tetrodotoxin in Nonhuman Primates. [PDF]

Invest Ophthalmol Vis Sci
Kwaw RJ, Duffy KR, Meng H, Jones RW, Zehra Z, Heynen AJ, Lawrence MS, Tychsen L, Bear MF, Frishman LJ, Patel NB, Das VE.   +11 more
europepmc   +1 more source